- Home
- EOLS vs PRAX Comparison
EOLS vs PRAX Comparison
Compare EOLS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOLS
- PRAX
- Stock Information
- Founded
- EOLS 2012
- PRAX 2015
- Country
- EOLS United States
- PRAX United States
- Employees
- EOLS N/A
- PRAX N/A
- Industry
- EOLS Biotechnology: Pharmaceutical Preparations
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- EOLS Health Care
- PRAX Health Care
- Exchange
- EOLS Nasdaq
- PRAX Nasdaq
- Market Cap
- EOLS 854.0M
- PRAX 730.1M
- IPO Year
- EOLS 2018
- PRAX 2020
- Fundamental
- Price
- EOLS $12.05
- PRAX $38.66
- Analyst Decision
- EOLS Strong Buy
- PRAX Strong Buy
- Analyst Count
- EOLS 4
- PRAX 10
- Target Price
- EOLS $24.67
- PRAX $123.80
- AVG Volume (30 Days)
- EOLS 736.2K
- PRAX 527.3K
- Earning Date
- EOLS 03-04-2025
- PRAX 05-12-2025
- Dividend Yield
- EOLS N/A
- PRAX N/A
- EPS Growth
- EOLS N/A
- PRAX N/A
- EPS
- EOLS N/A
- PRAX N/A
- Revenue
- EOLS $266,274,000.00
- PRAX $8,553,000.00
- Revenue This Year
- EOLS $34.56
- PRAX N/A
- Revenue Next Year
- EOLS $32.26
- PRAX $2,780.59
- P/E Ratio
- EOLS N/A
- PRAX N/A
- Revenue Growth
- EOLS 31.76
- PRAX 249.53
- 52 Week Low
- EOLS $9.25
- PRAX $30.01
- 52 Week High
- EOLS $17.82
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- EOLS 35.35
- PRAX 36.27
- Support Level
- EOLS $13.07
- PRAX $33.10
- Resistance Level
- EOLS $13.66
- PRAX $39.22
- Average True Range (ATR)
- EOLS 0.58
- PRAX 2.45
- MACD
- EOLS -0.15
- PRAX 1.52
- Stochastic Oscillator
- EOLS 22.22
- PRAX 83.99
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.